We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+18.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$29.7M
Cap. Flow
+$9.23M
Cap. Flow %
6.1%
Top 10 Hldgs %
42.62%
Holding
71
New
15
Increased
21
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.74M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.78M
3
GILD icon
Gilead Sciences
GILD
+$3.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.72M
5
MRK icon
Merck
MRK
+$2.59M

Top Sells

Rank Stock Value
1
TECH icon
Bio-Techne
TECH
+$4.35M
2
CPHD
Cepheid Inc
CPHD
+$4.07M
3
AZN icon
AstraZeneca
AZN
+$2.85M
4
BIIB icon
Biogen
BIIB
+$2.01M
5
MTD icon
Mettler-Toledo International
MTD
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Miscellaneous 14.74%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBB icon
1
iShares Biotechnology ETF
IBB
$10.8B
$10.7M 7.06%
94,800
+34,800
+58% +$3.78M
ALKS icon
2
Alkermes
ALKS
$8.2B
$6.94M 4.58%
87,415
+551
+0.6% +$38.6K
IONS icon
3
Ionis Pharmaceuticals
IONS
$10.4B
$6.34M 4.19%
102,459
+1,058
+1% +$57.1K
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$6.29M 4.15%
32,969
-52
-0.2% -$9.08K
NKTR icon
5
Nektar Therapeutics
NKTR
$2.55B
$5.87M 3.88%
23,239
-6,378
-22% -$1.31M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$83.2B
$5.82M 3.84%
10,714
+87
+0.8% +$47.1K
AMGN icon
7
Amgen
AMGN
$236B
$5.81M 3.84%
35,773
+30,147
+536% +$4.74M
CELG
8
DELISTED
Celgene Corp
CELG
$5.74M 3.79%
47,956
+819
+2% +$94.8K
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$5.7M 3.77%
127,088
+2,530
+2% +$105K
BMY icon
10
Bristol-Myers Squibb
BMY
$137B
$5.3M 3.5%
77,100
+41,100
+114% +$2.72M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$139B
$5.24M 3.46%
41,662
+786
+2% +$94.9K
INCY icon
12
Incyte
INCY
$25.9B
$5.21M 3.44%
48,045
+645
+1% +$71.9K
MRK icon
13
Merck
MRK
$369B
$4.75M 3.14%
94,320
+51,352
+120% +$2.59M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$31.7B
$4.73M 3.12%
50,222
+1,774
+4% +$164K
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$12.6B
$4.6M 3.04%
43,870
+1,858
+4% +$194K
QGENF
16
DELISTED
QIAGEN NV
QGENF
$4.42M 2.92%
160,000
– –
MDVN
17
DELISTED
MEDIVATION, INC.
MDVN
$4.41M 2.92%
91,310
-27,062
-23% -$1.17M
ILMN icon
18
Illumina
ILMN
$34.4B
$4.35M 2.87%
23,277
-5,850
-20% -$944K
GILD icon
19
Gilead Sciences
GILD
$185B
$3.41M 2.25%
33,700
+29,377
+680% +$3.06M
MTD icon
20
Mettler-Toledo International
MTD
$28.2B
$3.29M 2.17%
9,700
-5,500
-36% -$1.76M
BIIB icon
21
Biogen
BIIB
$32.7B
$3.21M 2.12%
10,482
-6,985
-40% -$2.01M
ADMS
22
DELISTED
Adamas Pharmaceuticals
ADMS
$2.27M 1.5%
+80,000
New +$1.35M
AGIO icon
23
Agios Pharmaceuticals
AGIO
$2.05B
$2.21M 1.46%
34,000
-12,000
-26% -$787K
EPZM
24
DELISTED
Epizyme, Inc
EPZM
$2.17M 1.44%
135,627
+89,548
+194% +$1.33M
HOLX
25
DELISTED
Hologic
HOLX
$1.86M 1.23%
48,000
– –
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opus Point Partners Management held 71 positions worth $151M, down 16% from $181M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management deployed $9.23M of net new capital in Q4 2015, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was Loxo Oncology, Inc: 60,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $2.85M trimmed.

  • Opus Point Partners Management's largest Q4 2015 buy was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
  • Opus Point Partners Management added most to Amgen in Q4 2015, an estimated $4.74M increase.
  • Opus Point Partners Management's biggest Q4 2015 reduction was AstraZeneca, cutting an estimated $2.85M.
  • Opus Point Partners Management fully exited Bio-Techne in Q4 2015, selling an estimated $4.35M.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $151M portfolio in Q4 2015.
  • Opus Point Partners Management opened 15 new positions and closed 14 in Q4 2015.
  • Opus Point Partners Management's portfolio value fell 16% quarter-over-quarter to $151M.

Based on Opus Point Partners Management's 13F filing for Q4 2015, filed 16 Feb 2016.